151979-08-7

Upstream product

• 4244-84-2 ethyl β-alaninate hydrochloride 
• 42454-06-8 2-nitro-5-hydroxybenzaldehyde 
• 151979-07-6 α-(3-carboxy-4-nitrophenoxy)-p-tolunitrile 
• 151979-06-5 α-(3-formyl-4-nitrophenoxy)-p-tolunitrile 
• 17201-43-3 4-cyanobenzyl bromide 

Downstream Products

• 151979-09-8 N-(5-(4-cyanobenzyloxy)-2-aminobenzoyl)-β-alanine ethyl ester 
• 151979-05-4 1-methyl-4-(2-carboxyethyl)-7-(4-cyanobenzyloxy)-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione ethyl ester 
• 167853-99-8 7-[[4-cyanophenyl]methoxy]-3,4-dihydro-1H-1,4-benzodiazepine-2-thione-5-one-4-propanoic acid ethyl ester 
• 201552-68-3 7-[[4-cyanophenyl]methoxy]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione-4-propanoic acid ethyl ester 
• 167854-21-9 7-[[4-cyanophenyl]methoxy]-2-methylmercaptyl-3,4-dihydro-1,4-benzodiazepine-5-one-4-propanoic acid ethyl ester 
• 167853-87-4 N-(5-(4-cyanobenzyloxy)-2-(bromoacetyl)aminobenzoyl)-β-alanine ethyl ester 
• 167854-00-4 8-[[4-cyanophenyl]methoxy]-1-methyl-6-oxo-4H-imidazo[1,2-a][1,4]benzodiazepine-5(6H)-propanoic acid ethyl ester 
• 167854-01-5 8-[[4-cyanophenyl]methoxy]-1-methyl-6-oxo-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine-5(6H)-propanoic acid ethyl ester 
• 167854-03-7 8-[[4-cyanophenyl]methoxy]-7,13-dihydro-5,13-dioxo-quinazolino[3,2-a][1,4]benzodiazepine-6(5H)-propanoic acid ethyl ester 
• 167854-04-8 8-[[4-(iminoaminomethyl)phenyl]methoxy]-7,13-dihydro-5,13-dioxo-quinazolino[3,2-a][1,4]benzodiazepine-6(5H)-propanoic acid ethyl ester 

Relevant academic research and scientific papers

Preparation and biological activity of novel tricyclic GPIIb/IIIa antagonists

Antagonists of the glycoprotein GPIIb/IIIa are a promising class of antithrombotic agents offering potential advantages over present antiplatelet agents (i.e., aspirin and ticlopidine). Novel tricyclic nonpeptidal GPIIb/IIIa antagonists have been prepared and evaluated in vitro as antagonists of fibrinogen binding to the purified GPIIb/IIIa receptor and as inhibitors of platelet aggregation. The work presented demonstrates the robustness of the benzodiazepinedione (BZDD) scaffold, which can be functionalized at the N1-C2 amide as well as at C7, to provide structural diversity and allow optimization of the physiochemical and pharmacological properties of the BZDD based GPIIb/IIIa antagonists. In addition, the resulting new class of tricyclic GPIIb/IIIa antagonists could be used to probe for additional binding interactions on the GPIIb/IIIa receptor and perhaps lead to BZDD based GPIIb/IIIa antagonists with increased potency. The tricyclic molecules reported herein demonstrate that a heterocyclic ring can be fused to the benzodiazepinedione scaffold with retention of anti-aggregatory potency and in the case of tetrazole 30i, increased potency relative to the bicyclic analogue 1c. Copyright (C) 1998 Elsevier Science Ltd.